The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.
In contrast to all that, many investors prefer to focus on companies like Aier Eye Hospital Group (SZSE:300015), which has not only revenues, but also profits. While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing.
Check out our latest analysis for Aier Eye Hospital Group
How Quickly Is Aier Eye Hospital Group Increasing Earnings Per Share?
Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. Impressively, Aier Eye Hospital Group has grown EPS by 26% per year, compound, in the last three years. This has no doubt fuelled the optimism that sees the stock trading on a high multiple of earnings.
Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. While Aier Eye Hospital Group did well to grow revenue over the last year, EBIT margins were dampened at the same time. If EBIT margins are able to stay balanced and this revenue growth continues, then we should see brighter days ahead.
The chart below shows how the company's bottom and top lines have progressed over time. For finer detail, click on the image.
SZSE:300015 Earnings and Revenue History September 7th 2022
Fortunately, we've got access to analyst forecasts of Aier Eye Hospital Group's future profits. You can do your own forecasts without looking, or you can take a peek at what the professionals are predicting.
Are Aier Eye Hospital Group Insiders Aligned With All Shareholders?
Since Aier Eye Hospital Group has a market capitalisation of CN¥194b, we wouldn't expect insiders to hold a large percentage of shares. But we are reassured by the fact they have invested in the company. We note that their impressive stake in the company is worth CN¥41b. This totals to 21% of shares in the company. Enough to lead management's decision making process down a path that brings the most benefit to shareholders. So there is opportunity here to invest in a company whose management have tangible incentives to deliver.
It means a lot to see insiders invested in the business, but shareholders may be wondering if remuneration policies are in their best interest. Well, based on the CEO pay, you'd argue that they are indeed. For companies with market capitalisations over CN¥55b, like Aier Eye Hospital Group, the median CEO pay is around CN¥2.3m.
The Aier Eye Hospital Group CEO received CN¥1.1m in compensation for the year ending December 2021. That seems pretty reasonable, especially given it's below the median for similar sized companies. While the level of CEO compensation shouldn't be the biggest factor in how the company is viewed, modest remuneration is a positive, because it suggests that the board keeps shareholder interests in mind. It can also be a sign of good governance, more generally.
Is Aier Eye Hospital Group Worth Keeping An Eye On?
If you believe that share price follows earnings per share you should definitely be delving further into Aier Eye Hospital Group's strong EPS growth. If you still have your doubts, remember too that company insiders have a considerable investment aligning themselves with the shareholders and CEO pay is quite modest compared to similarly sized companiess. The overarching message here is that Aier Eye Hospital Group has underlying strengths that make it worth a look at. What about risks? Every company has them, and we've spotted 1 warning sign for Aier Eye Hospital Group you should know about.
The beauty of investing is that you can invest in almost any company you want. But if you prefer to focus on stocks that have demonstrated insider buying, here is a list of companies with insider buying in the last three months.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
投資一家能夠扭轉命運的公司所帶來的興奮,對一些投機者來説是一個巨大的吸引力,因此,即使是沒有收入、沒有利潤、業績不佳的公司,也能設法找到投資者。但現實是,當一家公司每年虧損時,在足夠長的時間內,投資者通常會承擔他們的損失份額。一家虧損的公司還沒有用盈利來證明自己,最終外部資本的流入可能會枯竭。
與此形成鮮明對比的是,許多投資者更傾向於關注像愛爾眼科醫院集團(上證所:300015),不僅有收入,而且有利潤。雖然這並不一定意味着它是否被低估了,但該業務的盈利能力足以證明它有一定的升值價值--特別是如果它在增長的話。
查看我們對愛爾眼科醫院集團的最新分析
愛爾眼科醫院集團每股收益增長速度有多快?
一般來説,經歷每股收益(EPS)增長的公司應該會看到類似的股價趨勢。因此,有很多投資者喜歡購買每股收益不斷增長的公司的股票。令人印象深刻的是,艾爾眼科醫院集團在過去三年中以每年26%的複合增長率增長每股收益。這無疑助長了人們的樂觀情緒,認為該股的市盈率很高。
仔細考慮收入增長和息税前利潤(EBIT)利潤率有助於瞭解最近利潤增長的可持續性。雖然艾爾眼科醫院集團去年的收入增長良好,但息税前利潤也受到了抑制。如果息税前利潤能夠保持平衡,收入增長繼續下去,那麼我們應該會看到未來更光明的日子。
下面的圖表顯示了該公司的利潤和收入是如何隨着時間的推移而變化的。要查看更詳細的信息,請點擊圖片。
深交所:300015年度盈利及收入歷史2022年9月7日
幸運的是,我們已經獲得了艾爾眼科醫院集團的分析師預測未來利潤。你可以不看就做你自己的預測,或者你可以偷看一下專業人士的預測。
艾爾眼科醫院集團內部人士是否與所有股東一致?
由於愛爾眼科醫院集團的市值為人民幣1940億元,我們預計內部人士不會持有很大比例的股份。但讓我們放心的是,他們對該公司進行了投資。我們注意到他們在該公司令人印象深刻的股份價值410億元人民幣。這相當於該公司21%的股份。足以引導管理層的決策過程走上為股東帶來最大利益的道路。因此,這裏有機會投資於一家管理層具有切實激勵措施的公司。
看到內部人士投資於這項業務意義重大,但股東們可能會想,薪酬政策是否符合他們的最佳利益。嗯,根據CEO的薪酬,你會説他們確實是這樣的。對於市值超過550億加元的公司,如愛爾眼科醫院集團,CEO薪酬中值約為230萬加元。
這位愛爾眼科醫院集團首席執行官在截至2021年12月的一年中獲得了110萬加元的薪酬。這似乎相當合理,特別是考慮到它低於類似規模公司的中值。雖然CEO的薪酬水平不應該是人們如何看待公司的最大因素,但適度的薪酬是一個積極的因素,因為它表明董事會考慮到了股東的利益。更廣泛地説,這也可能是良好治理的標誌。
愛爾眼科醫院集團值得關注嗎?
如果你相信股價跟隨每股收益,你肯定應該進一步研究艾爾眼科醫院集團強勁的每股收益增長。如果你仍有疑問,還請記住,公司內部人士有相當大的投資來與股東保持一致,與類似規模的公司相比,CEO的薪酬相當低。這裏最重要的信息是,艾爾眼科醫院集團擁有潛在的優勢,值得一看。那麼風險呢?每家公司都有它們,我們已經發現愛爾眼科醫院集團的1個警告標誌你應該知道。
投資的美妙之處在於,你幾乎可以投資任何你想投資的公司。但如果你更願意關注那些表現出內幕收購的股票,這裏有一份過去三個月內有內幕收購的公司名單。
請注意,本文中討論的內幕交易指的是相關司法管轄區內的應報告交易。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。